Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProBioGen has entered a multi-program license deal with Inhibrx for GlymaxX ADCC-enhanced therapeutic antibodies development.
Subscribe to our email newsletter
ProBioGen’s GlymaxX ADCC enhancement technology, mammalian cell line development and manufacturing services will be employed to advance therapeutic antibodies developed by Inhibrx.
Under the terms of the collaboration, ProBioGen will receive both milestone-dependent license fees, as well as fee-for-service-based payments.
The financial details of the transaction have not been disclosed.